GlassScriptPhysician profile
Jatinchandra Patel
NPI 1801979901
$4,103.70
in general payments reported to CMS, 2019-2025
27 companies · $929 in 2025
The $929 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2020: $264 · 2021: $489 · 2022: $673 · 2023: $500 · 2024: $816 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,244.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $731.36 | 2020-2025 | Nexletol |
| Abiomed | $566.53 | 2019-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $517.79 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $477.14 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.12 | 2019-2025 | Jardiance |
| Medtronic, INC. | $217.31 | 2022-2025 | Linq II |
| Shockwave Medical, INC | $156.03 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $144.14 | 2019-2024 | Lux-Dx Insertable Cardiac Monitor, Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $120.77 | 2020-2025 | Lifevest |
| Penumbra, INC. | $115.47 | 2024-2025 | Indigo System |
| E.R. Squibb & Sons, L.L.C. | $115.13 | 2022-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $87.69 | 2021-2023 | |
| Daiichi Sankyo INC. | $76.91 | 2020-2024 | Injectafer |
| Pfizer INC. | $69.09 | 2020-2024 | |
| Amarin Pharma, INC. | $67.12 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $59.63 | 2021-2025 | Wegovy |
| Irhythm Technologies, INC. | $48.79 | 2020-2023 | Zio Xt Patch |
| Amgen INC. | $45.85 | 2022-2025 | Repatha |
| Merck Sharp & Dohme LLC | $42.50 | 2023-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $42.43 | 2022-2025 | |
| Baxter Healthcare | $35.86 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Biotronik INC. | $29.57 | 2025 | Amvia Edge |
| Biosense Webster, INC. | $29.53 | 2020 | |
| Heartflow, INC. | $18.68 | 2024 | |
| Sanofi-Aventis U.S. LLC | $16.30 | 2023 | |
| Tactile Systems Technology INC | $14.80 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jatinchandra Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.